Thomas J. Schall
CIK: 0001423084
Thomas J. Schall's purchase track record
How the stock did after each of Thomas J. Schall's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 4 since March 22, 2024
Stock higher 6 months later
100%
3 months: 75%
Median 6-month return
+58.3%
3 months: +74.5%
Beat the S&P 500
75%
median +47.7% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/15/2026 | IMRX | $101K | +20.0% | +3.0% | +8.5% |
| 6/27/2025 | IMRX | $35K | +128.9% | +90.6% | +12.3% |
| 6/17/2025 | IMRX | $89K | +356.6% | +215.4% | +13.7% |
| 3/22/2024 | IMRX | $7K | -43.9% | +25.9% | +8.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| IMRX | ▲ Buy | Open Market | 21,645 | $101K | 1/15/2026 | View on chart |
| IMRX | ▲ Buy | Open Market | 9,500 | $35K | 6/27/2025 | View on chart |
| IMRX | ▲ Buy | Open Market | 40,485 | $89K | 6/17/2025 | View on chart |
| IMRX | ▲ Buy | Open Market | 2,900 | $7K | 3/22/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Immuneering to Present Data at ESMO Congress 2026
Immuneering announced it will present data at the upcoming ESMO Congress in 2026. This event is relevant as it provides a future opportunity for the company to share clinical updates with the medical community. The stock is currently trading below its 52-week high, with analysts maintaining a wide range of price targets.
Immuneering to Present Data at ESMO Congress 2026. Immuneering announced it will present data at the upcoming ESMO Congress in 2026. This event is relevant as it provides a future opportunity for the company to share clinical updates with the medical community. The stock is currently trading below its 52-week high, with analysts maintaining a wide range of price targets.